EAM
KNSA icon

Eventide Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Eventide Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-37,807
Closed -$512K – 129
2019
Q2 		$512K Sell
37,807
-281,193
-88% -$4.36M 0.02% 115
2019
Q1 		$5.76M Hold
319,000
– – 0.2% 90
2018
Q4 		$8.96M Hold
319,000
– – 0.4% 71
2018
Q3 		$8.13M Buy
319,000
+22,600
+8% +$439K 0.3% 85
2018
Q2 		$5.14M Buy
+296,400
New +$5.36M 0.21% 91

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Eventide Asset Management's KNSA Position: Q3 2019 in Review

Eventide Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2019, closing a stake of 37,807 shares — an estimated $512K sold.

Eventide Asset Management first reported a position in KNSA in Q2 2018 and held it in 5 quarters. The position peaked at $8.96M in Q4 2018. 54 funds tracked by Wall St. Rank hold KNSA as of Q3 2019.

  • Eventide Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Eventide Asset Management sold 37,807 Kiniksa Pharmaceuticals shares in Q3 2019, an estimated $512K.
  • Eventide Asset Management first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 5 quarters.
  • Eventide Asset Management's Kiniksa Pharmaceuticals position peaked at $8.96M in Q4 2018.
  • 54 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2019.

Based on Eventide Asset Management's 13F filing for Q3 2019, filed 21 Nov 2019.